Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Health Policy
FDA Updates Mammography Regulations to Require Reporting of Breast Density Information
Women's Health
,
Breast Cancer
,
Health Policy
April 2023, Vol 14, No 2
The FDA has issued a final rule intended to ensure patients are better informed about their breast tissue density when undergoing mammography. The rule updates regulations first issued in the 1990s under the Mammography Quality Standards Act to oversee mammography facilities and improve breast cancer testing.
Read Article
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Health Policy
,
In the News
Web Exclusives
The Centers for Medicare & Medicaid Services (CMS) has broadened access to Medicare telehealth services so that beneficiaries can receive a wider range of services from their physicians without having to travel to a healthcare facility. Clinicians can bill immediately for services starting March 6, 2020.
Read Article
Understanding the Preventive Services Rule Changes
Health Policy
,
Policies & Guidelines
September 2010, Vol 1, No 4
On July 14, 2010, the Departments of Treasury, Labor, and Health and Human Services issued interim final rules for group health plans and health insurance issuers to provide detail on how those entities are to cover the preventive services required under the Patient Protection and Affordable Care Act (PPACA).
Read Article
REMS Regulation Provokes Anger in Provider Community
Health Policy
,
Policies & Guidelines
September 2010, Vol 1, No 4
Silver Spring, MD—Risk Evaluation and Mitigation Strategies (REMS) are required from some drug manufacturers as part of a new US Food and Drug Administration (FDA) regulation designed to draw the attention of sponsors, providers, and patients to the likelihood of severe adverse events accompanying certain drugs and biologic agents.
Read Article
The Impact of Policy and Politics on Health and Drug Pricing
By
Jessica Miller
Health Policy
,
Policies & Guidelines
December 2016, Vol 7, No 11
Washington, DC—A panel discussion on health and drug politics took place at the Sixth Annual Conference of the Association for Value-Based Cancer Care. The expert panel included Kavita Patel, MD, Johns Hopkins Medicine, Baltimore; Dan Todd, Principal of Todd Strategy, Washington, DC; and Liz Fowler, Vice President, Global Health Policy, Johnson & Johnson. The panel discussed what is working in healthcare, what is not, and where cancer care fits into it all.
Read Article
Is Direct-to-Consumer Advertising for Cancer Drugs Beneficial to Patients?
By
Jessica Miller
Health Policy
,
Policies & Guidelines
October 2016, Vol 7, No 9
Read Article
FDA Streamlines Expanded Access Application for Patients to Get Investigational Drugs
By
Nick Bryant
Health Policy
,
Policies & Guidelines
July 2016, Vol 7, No 6
The Individual Patient Expanded Access Application, which is designed to streamline the application procedure for individual patients who apply for expanded access to investigational therapeutics, including expanded access to drugs that are not in clinical trials, was recently updated by the FDA. Form FDA 3926 authorizes expanded access to investigational drugs for patients with serious or life-threatening conditions who have no therapeutic options.
Read Article
Proposed Reductions to Medicare Drug Payments Will Hurt Patients, Small Practices
By
Jessica Miller
Health Policy
,
Policies & Guidelines
July 2016, Vol 7, No 6
Opposition to proposed changes to the Medicare Part B payment for prescription drugs continues to grow since the Centers for Medicare & Medicaid Services (CMS) announced its plan in March 2016.
Read Article
New Oncology Care Model Focuses on Payment Reform and Value-Based Care
By
Jessica Miller
Health Policy
,
Value-Based Care
,
Policies & Guidelines
July 2016, Vol 7, No 6
A new payment and delivery model introduced by the Center for Medicare & Medicaid Innovation aims to align financial incentives to improve oncology care and outcomes. Expected to begin in July 2016, the program will target patients from the start of their chemotherapy through 6 months of care.
Read Article
Two Studies Point to Inadequate Evidence Supporting Many FDA Drug Approvals
By
Rosemary Frei, MSc
Health Policy
,
Policies & Guidelines
December 2015, Vol 6, No 11
Two related studies have documented significant deficiencies in the way the FDA approves expanded or new indications for drugs, using its expedited approval processes with limited evidence.
Read Article
Page 1 of 6
1
2
3
4
5
6
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma